헤더 로고

• All Rooms
• Galaxy Theater & Discovery Hall
• Galaxy Theater
• Discovery Hall
• Universe Arena
• Supernova Stage

March 26 (Thursday)

[JS01] Joint Session 01 (Asia Session): New Era of MPN Treatment Galaxy Theater

• March 26 (Thu), 09:00-10:15
• TBD
• 09:00-09:25 Advances and Insights in Molecular Monitoring for Myeloproliferative Neoplasms Hsin-An Hou (National Taiwan University Hospital, Taiwan) 09:25-09:50 Recent Therapeutic Advances in Early MF Winnie Teo (Alexandra Hospital, Singapore) 09:50-10:15 Optimizing Treatment Strategies in Higher MF and Beyond Sung-Eun Lee (College of Medicine, The Catholic University of Korea, Korea)

[SS01] Scientific Session 01: Novel Managements Tools for Hemophilia Discovery Hall

• March 26 (Thu), 09:00-10:15
• TBD
• 09:00-09:25 Recent Advances in the Diagnosis and Management of Acquired Hemophilia A Shin Young Hyun (Yonsei University College of Medicine, Korea) 09:25-09:50 Clinical Advances and Challenges in Gene Therapy Ben Samelson-Jones (The Children's Hospital of Philadelphia, USA) 09:50-10:15 Role of Bispecific Antibody in Hemophilia Claude Négrier (University of Lyon, France)

[SS02] Scientific Session 02: ALL 2026: Shifting Standards and Emerging Innovations Universe Arena

• March 26 (Thu), 09:00-10:15
• TBD
• 09:00-09:25 Integration of MRD and Genetics as a Therapeutic Guidepost in ALL Anthony Moorman (Newcastle University, UK) 09:25-09:50 Modern Immunotherapeutics in B-ALL: BiTEs, ADCs, and Beyond Jae-Ho Yoon (College of Medicine, The Catholic University of Korea, Korea) 09:50-10:15 Optimizing Frontline Therapy in Ph+ ALL: The Role of Ponatinib and Beyond Nicholas J. Short (The University of Texas MD Anderson Cancer Center, USA)

[ES01] Education Session 01: FOCUS ON: Indolent B-cell Lymphomas Supernova Stage

• March 26 (Thu), 09:00-10:15
• TBD
• 09:00-09:25 Mantle Cell Lymphoma Jaewon Hyung (University of Ulsan College of Medicine, Korea) 09:25-09:50 Chronic Lymphocytic Leukemia Jongheon Jung (National Cancer Center, Korea) 09:50-10:15 Marginal Zone Lymphoma Sang-A Kim (Seoul National University College of Medicine, Korea)

[PL01] Plenary Lecture 01 Galaxy Theater & Discovery Hall

• March 26 (Thu), 10:30-11:15
• TBD
• 10:30-11:15 Leukemic Stem Cells in 2026: Hierarchies, Heterogeneity, and Therapeutic Resistance John E. Dick (University Health Network, Canada)

[PS01] Presidential Symposium 01 Galaxy Theater & Discovery Hall

• March 26 (Thu), 11:15-12:00
• TBD
• 11:15-12:00 Targeted Treatment of Aggressive B-cell Lymphomas Wyndham H. Wilson (National Cancer Institute, USA)

[SS03] Scientific Session 03: Geriatric Hematology Discovery Hall

• March 26 (Thu), 15:25-16:40
• TBD
• 15:25-15:50 Integrating Comprehensive Geriatric Assessment into Hematology Practice: Identifying Frailty and Optimizing Care for Older Adults Jung-Yeon Choi (Seoul National University Bundang Hospital, Korea) 15:50-16:15 Redefining Risk in Elderly AML: The GA Approach Byung Sik Cho (College of Medicine, The Catholic University of Korea, Korea) 16:15-16:40 Psycho-oncological Interventions in Geriatric Hematology: Enhancing Quality of Life Juhee Cho (Samsung Advanced Institute for Health Sciences & Technology, Korea)

[SS04] Scientific Session 04: Next-Generation Cell Therapies: In Vivo CAR Engineering, Myeloid Modulation, and Beyond Universe Arena

• March 26 (Thu), 15:25-16:40
• TBD
• 15:25-15:50 Affinity Tuning and Cytokine Modulation in CAR-T and CAR-NK Therapy Challice Bonifant (Johns Hopkins University School of Medicine, USA) 15:50-16:15 Lessons from Hemophagocytic Lymphohistiocytosis: Taming the Cytokine Storm in CAR-T Cell Therapy Michael B. Jordan (Cincinnati Children’s Hospital Medical Center, USA) 16:15-16:40 Myeloid Cells as Mediators of Cell Therapy: From Suppression to Activations Seunghee Kim-Schulze (Icahn School of Medicine at Mount Sinai, USA)

[ES02] Education Session 02: Recent Advances in Acute Leukemia Supernova Stage

• March 26 (Thu), 15:25-16:40
• TBD
• 15:25-15:50 FLT3 Positive AML Ik-Chan Song (Chungnam National University College of Medicine, Korea) 15:50-16:15 B-cell ALL with High Risk Features in Adults Dong Won Baek (Kyungpook National University School of Medicine, Korea) 16:15-16:40 Understanding and Clinical Approach to Early T-cell Precursor Acute Lymphoblastic Leukemia (ETP-ALL) Hee Young Ju (Sungkyunkwan University School of Medicine, Korea)

[SS05] Scientific Session 05: MDS: Perspectives from Multiple Viewpoints Galaxy Theater

• March 26 (Thu), 16:55-18:10
• TBD
• 16:55-17:20 Insights into DDX41 Mutations: Relatively Common Genetic Aberrations in Korean MDS Patients Hongtae Kim (Ulsan National Institute of Science and Technology, Korea) 17:20-17:45 Few Drug Approvals in MDS: Lessons and Insights from a Decade of Clinical Trials Maximilian Stahl (Yale University School of Medicine, USA) 17:45-18:10 Clinical Approach to Relapsed or Refractory Lower-Risk Myelodysplastic Syndromes Valeria Santini (University of Florence, Italy)

[SS06] Scientific Session 06: Focus on Telomeres in Hematology Discovery Hall

• March 26 (Thu), 16:55-18:10
• TBD
• 16:55-17:20 Recent Advances in the Genetics of Telomere Biology Disorders Sharon A. Savage (National Institutes of Health, USA) 17:20-17:45 Role of Clonal Hematopoiesis in the Short Telomere Syndromes Kristen E. Schratz (Johns Hopkins University School of Medicine, USA) 17:45-18:10 Dyskeratosis Congenita and Related Telomere Biology Disorders Inderjeet Dokal (Queen Mary University of London, UK)

[SS07] Scientific Session 07: Advancing Immunotherapy in Multiple Myeloma: Mechanisms and Next-Generation Strategies Universe Arena

• March 26 (Thu), 16:55-18:10
• TBD
• 16:55-17:20 Next-Generation Effector Cells in Myeloma Immunotherapy Hyunsoo Cho (Seoul National University Hospital, Korea) 17:20-17:45 Natural Killer Cell-Based Immunotherapy in Multiple Myeloma Seung-Hwan Lee (University of Ottawa, Canada) 17:45-18:10 Resistant Mechanisms and Newer Immunogenic Targets in Relapsed or Refractory Multiple Myeloma Marta Chesi (Mayo Clinic, USA)

[ES03] Education Session 03: Integrated Laboratory Perspectives in Hematologic Malignancies: From Initial Workup to Transplantation Supernova Stage

• March 26 (Thu), 16:55-18:10
• TBD
• 16:55-17:20 Procedures and Interpretation of Bone Marrow Examination Seung Yeob Lee (Jeonbuk National University Medical School, Korea) 17:20-17:45 Diagnostic and Monitoring Approaches Focused on Minimal Residual Disease Miyoung Kim (University of Ulsan College of Medicine, Korea) 17:45-18:10 Blood Bank Testing before and after Hematopoietic Stem Cell Transplantation Dong Wook Jekarl (College of Medicine, The Catholic University of Korea, Korea)

March 27 (Friday)

[SS08] Scientific Session 08: Microbiome-Driven Precision Medicine in Hematology Discovery Hall

• March 27 (Fri), 09:00-10:15
• TBD
• 09:00-09:25 Microbial Molecules as Emerging Biomarkers in Hematologic Diseases Christoph K. Stein-Thoeringer (University Clinic Tübingen, Germany) 09:25-09:50 Gut Microbiome as a Predictive Biomarker and Emerging Intervention Target in DLBCL Woorim Kang (Kangwon National University, Korea) 09:50-10:15 Microbiome in Allogeneic Hematopoietic Cell Transplantation & Immunotherapy Jonathan U. Peled (Memorial Sloan Kettering Cancer Center, USA)

[SS09] Scientific Session 09: Future of Immunotherapy in DLBCL Universe Arena

• March 27 (Fri), 09:00-10:15
• TBD
• 09:00-09:25 A Personalized Approach to Immune Therapies for Cancer: One Drug, One Patient Larry W. Kwak (City of Hope, USA) 09:25-09:50 Paradigm Shift of DLBCL Treatment Based on Bispecific Abs Won Seog Kim (Sungkyunkwan University School of Medicine, Korea) 09:50-10:15 Paradigm shift of DLBCL Treatment Based on MRD-Driven Approach Ash A. Alizadeh (Stanford University, USA)

[ES04] Education Session 04: Understanding Anemia Supernova Stage

• March 27 (Fri), 09:00-10:15
• TBD
• 09:00-09:25 Iron Deficiency & Iron Metabolism Jeong-Ok Lee (Seoul National University College of Medicine, Korea) 09:25-09:50 Hereditary Hemolytic Anemia Heewon Chueh (Inje University Haeundae Paik Hospital, Korea) 09:50-10:15 Cold Agglutinin Disease Dae-Ho Choi (Sungkyunkwan University School of Medicine, Korea)

[PL02] Plenary Lecture 02 Galaxy Theater & Discovery Hall

• March 27 (Fri), 10:30-11:15
• TBD
• 10:30-11:15 The Present and Future of Hematopoietic Stem Cell Gene Therapies Cynthia E. Dunbar (National Institutes of Health, USA)

[SS10] Scientific Session 10: Pediatric Malignancies: From Patients to Survivors Discovery Hall

• March 27 (Fri), 15:05-16:20
• TBD
• 15:05-15:30 Menin Inhibitors and Epigenetic Therapy in KMT2A-rearranged ALL Elisabeth Salzer (St. Anna Children's Hospital, Austria) 15:30-15:55 Virus-specific and Next-generation T-cell Therapy in Pediatric Hematologic Malignancy Catherine Bollard (Children’s National Hospital, USA) 15:55-16:20 Pediatric Cancer Survivorship and Long-Term Toxicities Sharon M. Castellino (Emory University School of Medicine, USA)

[SS11] Scientific Session 11: Transforming the Therapeutic Landscape of AML: From Biology to Targeted Therapies Universe Arena

• March 27 (Fri), 15:05-16:20
• TBD
• 15:05-15:30 Leukemia Stem Cells, Clonal Evolution, and Immune Evasion in AML: Translational Insights and Therapeutic Opportunities Ravindra Majeti (Stanford University, USA) 15:30-15:55 Menin Inhibition in AML: Evolving Frontiers in Targeted Therapy Eytan M. Stein (Memorial Sloan Kettering Cancer Center, USA) 15:55-16:20 HMA + Venetoclax + Targeted Agents: Clinical Evidence and Future of Triplet Therapy in AML Tapan Kadia (The University of Texas MD Anderson Cancer Center, USA)

[ES05] Education Session 05: Big Data and AI in Hematology Research Supernova Stage

• March 27 (Fri), 15:05-16:20
• TBD
• 15:05-15:30 Real-World Effectiveness of Immunotherapy in Hematologic Malignancies: Evidence from Big Data Sung-Soo Park (College of Medicine, The Catholic University of Korea, Korea) 15:30-15:55 Digital Healthcare Innovation: Real-World Applications of Big Data and AI Yoon Sup Choi (Digital Healthcare Partners, Korea) 15:55-16:20 Wise Hematology Life: Use of AI Ki-Hyun Jeon (Seoul National University College of Medicine, Korea)

[SS12] Scientific Session 12: Expanding Therapeutic Horizons in ITP and TTP Discovery Hall

• March 27 (Fri), 16:35-17:50
• TBD
• 16:35-17:00 Real World Long Term TPO-RA: Sustaining Remission or Time to Stop? Nichola Cooper (Imperial College Healthcare NHS Trust, UK) 17:00-17:25 A New Chapter in ITP management - Updated trials Jun Ho Jang (Sungkyunkwan University School of Medicine, Korea) 17:25-17:50 Caplacizumab and the Changing Landscape of TTP Management Shruti Chaturvedi (Johns Hopkins University School of Medicine, USA)

[SS13] Scientific Session 13: Other Plasma Cell Disorders: From Diagnosis to Mechanistic Insights Universe Arena

• March 27 (Fri), 16:35-17:50
• TBD
• 16:35-17:00 AL Amyloidosis: A Comprehensive Update from Fundamentals to Emerging Therapies Efstathios Kastritis (National and Kapodistrian University of Athens, Greece) 17:00-17:25 Monoclonal Gammopathy and the Kidney: A Comprehensive Approach to MGRS Nelson Leung (Mayo Clinic, USA) 17:25-17:50 POEMS Syndrome: From Longitudinal Clinical Experience to Translational Insights Emiko Sakaida (Chiba University Hospital, Japan)

[ES06] Education Session 06: Toxicity Masterclass: Managing CRS, Cytopenia, and Infections in T Cell Engaging Therapies Supernova Stage

• March 27 (Fri), 16:35-17:50
• TBD
• 16:35-17:00 CRS and ICANS: Early Detection and Personalized Management Jinchul Kim (Inha University College of Medicine, Korea) 17:00-17:25 Prolonged Cytopenia after TCEs: Mechanisms, Biomarkers, and Risk Stratification Sang Eun Yoon (Sungkyunkwan University School of Medicine, Korea) 17:25-17:50 Preventing Infections in TCEs: Risk Stratification and Prophylaxis Ja Min Byun (Seoul National University College of Medicine, Korea)

March 28 (Saturday)

[JS05] Joint Session 05 (Asia Session) Galaxy Theater

• March 28 (Sat), 09:00-10:15
• TBD
• 09:00-09:25 Current Practice and Research in T-cell and NK/T-cell Lymphoma in Japan Motoko Yamaguchi (Mie University Graduate School of Medicine, Japan) 09:25-09:50 Research Progress of NK/ T-Cell Lymphoma: Experience from China Huangming Hong (Sichuan Cancer Hospital, China) 09:50-10:15 Clinical and Translational Research in T-cell and NK/T-cell Lymphoma in Korea Seok Jin Kim (Sungkyunkwan University School of Medicine, Korea)

[SS14] Scientific Session 14: Germline Variants and Hematologic Malignancies: Current Understanding and Clinical Implications Discovery Hall

• March 28 (Sat), 09:00-10:15
• TBD
• 09:00-09:25 Clonal Evolution from Germline to Malignancy: Timing and Mechanisms Jyoti Nangalia (University of Cambridge, UK) 09:25-09:50 Inherited Myeloid Malignancies: From Genetic Diagnosis to Clinical Management Marc H.G.P. Raaijmakers (Erasmus MC Cancer Institute, The Netherlands) 09:50-10:15 Germline Predisposition Genes in Lymphoid Malignancies Susan L. Slager (Mayo Clinic, USA)

[SS15] Scientific Session 15: Exploring the Map of CML: Beyond BCR::ABL1 Universe Arena

• March 28 (Sat), 09:00-10:15
• TBD
• 09:00-09:25 Immunological Landscape of CML Kyung-Mi Lee (Korea University College of Medicine, Korea) 09:25-09:50 Integrating Biomarkers to Predict Response to TKIs Sin Tiong Ong (Duke-NUS Medical School, Singapore) 09:50-10:15 Drug Combination to Overcome Resistance Delphine Rea (Hôpital Saint-Louis, France)

[ES07] Education Session 07: Preventive and Supportive Approaches in Hematologic Malignancies Supernova Stage

• March 28 (Sat), 09:00-10:15
• TBD
• 09:00-09:25 Vaccination and Infection Prevention Seong Jin Choi (Seoul National University College of Medicine, Korea) 09:25-09:50 Cardiotoxicity: Risk Assessment and Prevention Hyukjin Park (Chonnam National University Medical School, Korea) 09:50-10:15 Chemotherapy-induced Peripheral Neuropathy Young Woo Jeon (College of Medicine, The Catholic University of Korea, Korea)

[PL03] Plenary Lecture 03 Galaxy Theater & Discovery Hall

• March 28 (Sat), 10:30-11:15
• TBD
• 10:30-11:15 High-risk Multiple Myeloma in 2026: Early Intervention, MRD-driven Therapy, and Beyond Philippe Moreau (University Hospital of Nantes, France)